These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 24311149)

  • 1. Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies.
    Davila ML; Bouhassira DC; Park JH; Curran KJ; Smith EL; Pegram HJ; Brentjens R
    Int J Hematol; 2014 Apr; 99(4):361-71. PubMed ID: 24311149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CAR therapy for hematological cancers: can success seen in the treatment of B-cell acute lymphoblastic leukemia be applied to other hematological malignancies?
    Pegram HJ; Smith EL; Rafiq S; Brentjens RJ
    Immunotherapy; 2015; 7(5):545-61. PubMed ID: 26065479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice.
    Luskin MR; DeAngelo DJ
    Curr Hematol Malig Rep; 2017 Aug; 12(4):370-379. PubMed ID: 28656487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Building upon the success of CART19: chimeric antigen receptor T cells for hematologic malignancies.
    Rotolo A; Karadimitris A; Ruella M
    Leuk Lymphoma; 2018 Sep; 59(9):2040-2055. PubMed ID: 29165008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor.
    Kochenderfer JN; Feldman SA; Zhao Y; Xu H; Black MA; Morgan RA; Wilson WH; Rosenberg SA
    J Immunother; 2009 Sep; 32(7):689-702. PubMed ID: 19561539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.
    Riaz IB; Zahid U; Kamal MU; Husnain M; McBride A; Hua A; Hamadani AA; George L; Zeeshan A; Sipra QR; Raina A; Rahman B; Puvvada S; Anwer F
    Immunotherapy; 2017 Sep; 9(12):979-993. PubMed ID: 28971751
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies.
    Nagle SJ; Garfall AL; Stadtmauer EA
    Cancer J; 2016; 22(1):27-33. PubMed ID: 26841014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia.
    Davila ML; Brentjens RJ
    Clin Adv Hematol Oncol; 2016 Oct; 14(10):802-808. PubMed ID: 27930631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells.
    Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W
    Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy.
    Gardner R; Wu D; Cherian S; Fang M; Hanafi LA; Finney O; Smithers H; Jensen MC; Riddell SR; Maloney DG; Turtle CJ
    Blood; 2016 May; 127(20):2406-10. PubMed ID: 26907630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
    Davila ML; Brentjens R
    Hematol Oncol Clin North Am; 2013 Apr; 27(2):341-53. PubMed ID: 23561477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors.
    Long AH; Haso WM; Shern JF; Wanhainen KM; Murgai M; Ingaramo M; Smith JP; Walker AJ; Kohler ME; Venkateshwara VR; Kaplan RN; Patterson GH; Fry TJ; Orentas RJ; Mackall CL
    Nat Med; 2015 Jun; 21(6):581-90. PubMed ID: 25939063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors.
    Thokala R; Olivares S; Mi T; Maiti S; Deniger D; Huls H; Torikai H; Singh H; Champlin RE; Laskowski T; McNamara G; Cooper LJ
    PLoS One; 2016; 11(8):e0159477. PubMed ID: 27548616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
    Friedman KM; Garrett TE; Evans JW; Horton HM; Latimer HJ; Seidel SL; Horvath CJ; Morgan RA
    Hum Gene Ther; 2018 May; 29(5):585-601. PubMed ID: 29641319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric Antigen Receptor (CAR) T Cells: Lessons Learned from Targeting of CD19 in B-Cell Malignancies.
    Hay KA; Turtle CJ
    Drugs; 2017 Mar; 77(3):237-245. PubMed ID: 28110394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD19 CAR-T Cells With Membrane-Bound IL-15 for B-Cell Acute Lymphoblastic Leukemia After Failure of CD19 and CD22 CAR-T Cells: Case Report.
    Sun Y; Su Y; Wang Y; Liu N; Li Y; Chen J; Qiao Z; Niu J; Hu J; Zhang B; Ning H; Hu L
    Front Immunol; 2021; 12():728962. PubMed ID: 34691036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eradication of B-ALL using chimeric antigen receptor-expressing T cells targeting the TSLPR oncoprotein.
    Qin H; Cho M; Haso W; Zhang L; Tasian SK; Oo HZ; Negri GL; Lin Y; Zou J; Mallon BS; Maude S; Teachey DT; Barrett DM; Orentas RJ; Daugaard M; Sorensen PH; Grupp SA; Fry TJ
    Blood; 2015 Jul; 126(5):629-39. PubMed ID: 26041741
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persuading natural killer cells to eliminate bad B cells.
    Cooper LJ
    Clin Cancer Res; 2009 Aug; 15(15):4790-1. PubMed ID: 19638468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T-cell therapies for multiple myeloma.
    Mikkilineni L; Kochenderfer JN
    Blood; 2017 Dec; 130(24):2594-2602. PubMed ID: 28928126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.